Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology

STEFANO FANTIProfessor-Department of Experimental, Diagnostic and Specialty Medicine - DIMESResearch interests are mainly focused on the use of PET in oncology, with particular reference to innovative radiopharmaceuticals. Engaged in national and international research projects, he collaborates with numerous institutions, including IAEA, EANMGOPINATH GNANASEGARANConsultant Physician in Nuclear Medicine at Royal Free London NHS Foundation Trust Hospital NHS Foundation Trust. His specialist interests are hybrid imaging and radionuclide therapy. Former Chair of the British Nuclear Medicine Society Education Committee.IGNASI CARRIOProfessor of Radiology and Nuclear Medicine at Autonomous University of Barcelona, and Director of the Department of Nuclear Medicine at Hospital Sant Pau in Barcelona, Spain. Main research and scientific activity in Nuclear Medicine and Molecular Imaging, in particular in the fields of Cardiovascular Medicine and Oncology. FormerEditor-in-Chief of the European Journal of Nuclear Medicine and Molecular Imaging. Former President of the European Association of Nuclear Medicine.

• PART I General Chapters: Introduction to Treatment response evaluation:  Science and Practice.- CT in Treatment response evaluation – Overview.- MRI & Diffusion weighted MRI in Treatment response evaluation- Overview.- PET & PET-CT in Treatment response evaluation-Overview.- Conventional Radiological Techniques and PET-CT in Treatment response evaluation in post-surgical setting.- Conventional Radiological Techniques and PET-CT in Treatment response evaluation in chemotherapy setting.- Conventional Radiological Techniques and PET-CT in Treatment response evaluation in radiation oncology.- Conventional Radiological Techniques and PET-CT in Treatment response evaluation in Immunotherapy settings.- Treatment response evaluation of bone metastases using 18F-NaF.- How to report PET-CT scans in post therapy scenarios: Do’s and don’ts.- PART II Atlas Articles: 18F-FDG  & Non FDG PET-CT in Treatment response evaluation in Head and neck cancer.- 18F-FDG  & Non FDG PET-CT in Treatment response evaluation in lung cancer.- 18F-FDG  & Non FDG PET-CT in Treatment response evaluation in neuro-oncology.- 18F-FDG  & Non FDG PET-CT in Treatment response evaluation in hepatobiliary cancer.- 18F-FDG  & Non FDG PET-CT in Treatment response evaluation in gastroesophageal cancer.- 18F-FDG & Non FDG PET-CT in Treatment response evaluation in Lymphoma and Non-hodgkins lymphoma.- 18F-FDG & Non FDG PET-CT in Treatment response evaluation in breast cancer.- 18F-FDG, 18F-Choline & 68Ga-PSMA PET-CT in Treatment response evaluation in prostate cancer.- 18F-FDG  & Non FDG PET-CT in Treatment response evaluation in gynaecological cancers.- 18F-FDG  & Non FDG PET-CT in Treatment response evaluation in colorectal cancer.- 18F-FDG  & Non FDG PET-CT in Treatment response evaluation in soft tissue sarcomas.- FDG  & Non FDG PET-CT in Treatment response evaluation in malignant melanoma.- 18F-FDG & Non FDG PET-CT in Treatment response evaluation in myeloma.- FDG PET-CT & 18F-NaF in Treatment response evaluation in bone metastases and bone tumours.- 18F-FDG  & Non FDG PET-CT in Assessment of treatment response in paediatric oncology.- 68Ga-DOTA PET-CT in Treatment response evaluation in NETs.- 18F-DOPA PET-CT in Treatment response evaluation.- 18F-FLT PET-CT in Treatment response evaluation.- Brain PET-CT in Treatment response evaluation.